The effects of pituitary adenylate cyclase activating polypeptide in renal ischemia/reperfusion

Acta Biologica Hungarica

Volumn 65, Issue 4, 2014, Pages 369-378

  László, Eszter ^a   Kiss, P ^a   Horváth, Gabriela ^a   Szakaly P ^a   Tamás, Andrea ^a   Reglodi, Dóra ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Ischemia reperfusion; Kidney; PACAP; Renoprotection

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

IMMUNOREACTIVITY; KIDNEY INJURY; KIDNEY ISCHEMIA; NONHUMAN; OXIDATIVE STRESS; REPERFUSION INJURY; REVIEW; ANIMAL; ENZYMOLOGY; HUMAN; KIDNEY; KIDNEY DISEASES; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; KIDNEY; KIDNEY DISEASES; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 84925284454     PISSN: 02365383     EISSN: 1588256X     Source Type: Journal    
DOI: 10.1556/ABiol.65.2014.4.1     Document Type: Review

References (52)

1. Arimura, A., Somogyvári-Vigh, A., Miyata, A., Mizuno, K., Coy, D. H., Kitada, C. (1991) Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 129, 2787-2789.
2. Arimura, A., Li, M., Batuman, V. (2006) Potential protective action of pituitary adenylate cyclase activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 107, 661-668.
3. Arimura, A., Li, M., Batuman, V. (2006) Treatment of renal failure associated with multiple myeloma and other diseases by PACAP-38. Ann. NY Acad. Sci. 1070, 14.
4. Atlasz, T., Babai, N., Kiss, P., Reglodi, D., Tamas, A., Szabadfi, K., Toth, G., Hegyi, O., Lubics, A., Gabriel, R. (2007) Pituitary adenylate cyclase activating polypeptide is protective in bilateral carotid occlusion-induced retinal lesion in rats. Gen. Comp. 153, 108-114.
5. Bánki, E., Degrell, P., Kiss, P., Kovacs, K., Kemeny, A., Csanaky, K., Duh, A., Nagy, D., Toth, G., Tamas, A., Reglodi, D. (2013) Effect of PACAP treatment on kidney morphology and cytokine expression in rat diabetic nephropathy. Peptides 42, 125-130.
6. Basile, D. P., Martin, D. R., Hammerman, M. R. (1998) Extracellular matrix-related genes in kidney after ischemic injury: potential role for TGF-beta in repair. Am. J. Physiol. 275, 894-903.
7. Brubel, R., Horvath, G., Reglodi, D., Lubics, A., Tamas, A., Kiss, P., Laszlo, E., Nemeth, J., Mark, L., Szakaly, P. (2011) Presence of pituitary adenylate cyclase activating polypeptide and its type I receptor in the rat kidney. Transplant. Proc. 43, 1297-1299.
8. Ferencz, A., Racz, B, Tamas, A., Reglodi, D., Lubics, A., Nemeth, J., Nedvig, K., Kalmar-Nagy, K., Horvath, O. P., Weber, G., Roth, E. (2009) Influence of PACAP on oxidative stress and tissue injury following small bowel autotransplantation. J. Mol. Neurosci. 37, 168-176.
9. Ferencz, A., Kiss, P., Weber, Gy., Helyes, Z., Shintani, N., Baba, A., Reglodi, D. (2010) Comparison of intestinal warm ischemic injury in PACAP knockout and wild-type mice. J. Mol. Neurosci. 42, 435-442.
10. Ferencz, A., Weber, Gy., Helyes, Z., Hashimoto, H., Baba, A., Reglodi, D. (2010) Presence of endogenous PACAP-38 ameliorated intestinal cold preservation tissue injury. J. Mol. Neurosci. 42, 428-434.
11. Gardiner, S. M., Rakhit, T., Kemp, P. A., March, J. E., Bennett, T. (1994) Regional haemodynamic responses to pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in conscious rats. Br. J. Pharmacol. 111, 589-597.
12. Harmar, A. J., Sheward, W. J., Morrison, C. F., Waser, B., Gugger, M., Reubi, J. C. (2004) Distribution of the VPAC 2 receptor in peripheral tissues of the mouse. Endocrinology 145, 1203-1210.
13. Hautmann, M., Friis, U. G., Desch, M., Todorov, V., Castrop, H., Segerer, F., Otto, C., Schutz, G., Schweda, F. (2007) Pituitary adenylate cyclase activating polypeptide stimulates renin secretion via activation of PAC1 receptors. J. Am. Soc. Nephrol. 18, 1150-1156.
14. Horvath, G., Mark, L., Brubel, R., Szakaly, P., Racz, B., Kiss, P., Tamas, A., Helyes, Z., Lubics, A., Hashimoto, H., Baba, A., Shintani, S., Furjes, G., Nemeth, J., Reglodi, D. (2010) Mice deficient in pituitary adenylate cyclase activating polypeptide display increased sensitivity to renal oxidative stress in vitro. Neurosci. Lett. 469, 70-74.
15. Horvath, G., Racz, B., Reglodi, D., Kovacs, K., Kiss, P., Gallyas Jr., F., Bognar, Z., Szabo, A., Magyarlaki, T., Laszlo, E., Lubics, A., Tamas, A., Toth, G., Szakaly, P. (2010) Effects of PACAP on mitochondrial apoptotic pathways and cytokine expression in rats subjected to renal ischemia/reperfusion. J. Mol. Neurosci. 42, 411-418.
16. Horvath, G., Racz, B., Szakaly, P., Kiss, P., Laszlo, E., Hau, L., Tamas, A., Helyes, Z., Lubics, A., Hashimoto, H., Baba, A., Reglodi, D. (2010) Mice deficient in neuropeptide PACAP demonstrate increased sensitivity to in vitro kidney hypoxia. Transplant. Proc. 42, 2293-2295.
17. Horvath, G., Brubel, R., Kovacs, K., Reglodi, D., Opper, B., Ferencz, A., Szakaly, P., Laszlo, E., Hau, L., Kiss, P., Tamas, A., Racz, B. (2011) Effects of PACAP on oxidative stress-induced cell death in primary rat kidney and human hepatocyte cell cultures. J. Mol. Neurosci. 43, 67-75.
18. Jain, S., Bicknell, G. R., Nicholson, M. L. (2000) Molecular changes in extracellular matrix turnover after renal ischemia-reperfusion injury. Br. J. Surg. 87, 1188-1192.
19. Jang, H. R., Gandolfo, M. T., Ko, G. J., Satpute, S. R., Racusen, L., Rabb, H. (2010) B cells limit repair after ischemic acute kindey injury. J. Am. Soc. Nephrol. 21, 654-665.
20. Ji, H., Zhang, Y., Shen, X. D., Gao, F., Huang, C. Y., Abad, C., Busuttil, R. W., Waschek, J. A., Kupiec-Weglinski, J. W. (2013) Neuropeptide PACAP in mouse liver ischemia and reperfusion injury: immunomodulation by the cAMP-PKA pathway. Hepatology 57, 1225-1237.
21. Khan, A. M., Li, M., Brant, E., Maderdrut, J. L., Majid, D. S. A., Simon, E. E., Batuman, V. (2011) Renoprotection with pituitary adenylate cyclase activating polypeptide in cyclosporin A-induced nephrotoxicity. J. Invest. Med. 59, 793-802.
22. Khan, A. M., Li, M., Abdulnour-Nakhoul, S., Maderdrut, J. L., Simon, E. E., Batuman, V. (2012) Delayed administration of pituitary adenylate cyclase-activating polypeptide 38 ameliorates renal ischemia/reperfusion injury in mice by modulating Toll-like receptors. Peptides 38, 395-403.
23. Laburthe, M., Couvineau, A., Tan, V. (2007) Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 28, 1631-1639.
24. Lam, H. C., Takahashi, K., Ghatei, M. A., Kanse, S. M., Polak, J. M., Bloom, S. R. (1990) Binding sites of a novel neuropeptide pituitary adenylate cyclase activating polypeptide in the rat brain and lung. Eur. J. Biochem. 193, 725-729.
25. Li, M., Cortez, S., Nakamachi, T., Batuman, V., Arimura, A. (2006) Pituitary adenylate cyclase activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells. Cancer Res. 66, 8796-8803.
26. Li, M., Maderdrut, J. L., Lertora, J. J. L., Batuman, V. (2007) Intravenous infusion of pituitary adenylate cyclase activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study. Peptides 28, 1891-1895.
27. Li, M., Maderdrut, J. L., Lertora, J. J. L., Arimura, A., Batuman, V. (2008) Renoprotection by pituitary adenylate cyclase activating polypeptide in multiple myeloma and other kidney diseases. Regul. Pept. 145, 24-32.
28. Li, M., Balamuthusamy, S., Khan, A. M., Maderdrut, J. L., Simon, E. E., Batuman, V. (2010) Pituitary adenylate cyclase activating polypeptide ameliorates cisplatin-induced acute kidney injury. Peptides 31, 592-602.
29. Li, M., Khan, A. M., Maderdrut, J. L., Simon, E. E., Batuman, V. (2010) The effect of PACAP38 on MyD88-mediated signal transduction in ischemia/hypoxia-induced acute kidney injury. Am. J. Nephrol. 32, 522-532.
30. Li, M., Balamuthusamy, S., Khan, A. M., Maderdrut, J. L., Simon, E. E., Batuman, V. (2011) Pituitary adenylate cyclase activating polypeptide prevents cisplatin-induced renal failure. J. Mol. Neurosci. 43, 58-66.
31. Menger, M. D., Vollmar, B. (2007) Pathomechanisms of ischemia-reperfusion injury as the basis for novel preventive strategies: is it time for the introduction of pleiotropic compounds? Transplant. Proc. 39, 485-488.
32. Reglodi, D., Somogyvari-Vigh, A., Vigh, S., Kozicz, T., Arimura, A. (2000) Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke 31, 1411-1417.
33. Reglodi, D., Kiss, P., Lubics, A., Tamas, A. (2011) Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr. Pharm. Des. 17, 962-972.
34. Reglodi, D., Kiss, P., Horvath, G, Lubics, A., Laszlo, E., Tamas, A., Racz, B., Szakaly, P. (2012) Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney. Neuropeptides 46, 61-70.
35. Reglodi, D., Kiss, P., Szabadfi, K., Atlasz, T., Gabriel, R., Horvath, G., Szakaly, P., Sandor, B., Lubics, A., Laszlo, E., Farkas, J., Matkovits, A., Brubel, R., Hashimoto, H., Ferencz, A., Vincze, A., Helyes, Z., Welke, L., Lakatos, A., Tamas, A. (2012) PACAP is an endogenous protective factor-insights from PACAP-deficient mice. J. Mol. Neurosci. 48, 482-492.
36. Reubi, J. C. (2000) In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann. NY Acad. Sci. 921, 1-25.
37. Reubi, J. C., Laderach, U., Waser, B., Gebbers, J. O., Robberecht, P., Laissue, J. A. (2000) Vasoactive intestinal peptide/pituitary adenylate cyclase activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 60, 3105-3112.
38. Riera, M., Torras, J., Cruzado, J. M., Lloberas, N., Liron, J., Herrero, I., Navarro, M. A., Grinyo, J. M. (2001) The enhancement of endogenous cAMP with pituitary adenylate cyclase activating polypeptide protects rat kidney against ischemia through the modulation of inflammatory response. Transplantation 72, 1217-1223.
39. Roth, E., Weber, G., Kiss, P., Horvath, G., Toth, G., Gasz, B., Ferencz, A., Gallyas, F. Jr., Reglodi, D., Racz, B. (2009) Effects of PACAP and preconditioning against ischemia/reperfusion-induced cardiomyocyte apoptosis in vitro. Ann. NY Acad. Sci. 1163, 512-516.
40. Saikumar, P., Venkatachalam, M. A. (2003) Role of apoptosis in hypoxic/ischemic damage in the kidney. Semin Nephrol. 23, 511-521.
41. Seaborn, T., Masmoudi-Kouli, O., Fournier, A., Vaudry, H., Vaudry, D. (2011) Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis. Curr. Pharm. Des. 17, 204-214.
42. Somogyvari-Vigh, A., Reglodi, D. (2004) Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Curr. Pharm. Des. 10, 2861-2889.
43. Szabadfi, K., Atlasz, T., Kiss, P., Danyadi, B., Tamas, A., Helyes, Z., Hashimoto, H., Shintani, N., Baba, A., Toth, G., Gabriel, R., Reglodi, D. (2012) Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) are more susceptible to retinal ischemic injury in vivo. Neurotox. Res. 21, 41-48.
44. Szakaly, P., Kiss, P., Lubics, A., Magyarlaki, T., Tamas, A., Racz, B., Lengvari, I., Toth, G., Reglodi, D. (2008) Effects of PACAP on survival and renal morphology in rats subjected to renal ischemia- reperfusion. J. Mol. Neurosci. 36, 89-96.
45. Szakaly, P., Horvath, G., Kiss, P., Laszlo, E., Farkas, J., Furjes, G., Nemeth, J., Reglodi, D. (2010) Changes in pituitary adenylate cyclase activating polypeptide following renal ischemia-reperfusion in rats. Transplant. Proc. 42, 2283-2286.
46. Szakaly, P., Laszlo, E., Kovacs, K., Racz, B., Horvath, G., Ferencz, A., Lubics, A., Kiss, P., Tamas, A., Brubel, R., Opper, B., Baba, A., Hashimoto, H., Farkas, J., Matkovits, A., Magyarlaki, T., Helyes, Zs., Reglodi, D. (2011) Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) show increased susceptibility to in vivo renal ischemia/reperfusion injury. Neuropeptides 45, 113-121.
47. Tamas, A., Reglodi, D., Farkas, O., Kovesdi, E., Pal, J., Povlishock, J. T., Schwarcz, A., Czeiter, E., Szanto, Z., Doczi, T., Buki, A., Bukovics, P. (2012) Effect of PACAP in central and peripheral nerve injuries. Int. J. Mol. Sci. 13, 8430-8448.
48. Uchida, D., Arimura, A., Somogyvari-Vigh, A., Shioda, S., Banks, W. A. (1996) Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain Res. 736, 280-286.
49. Vannay, A., Fekete, A., Langer, R., Toth, T., Sziksz, E., Vasarhelyi, B., Szabo, A. J., Losonczy, G., Adori, C., Gal, A., Tulassay, T., Szabo, A. (2009) Dehydroepiandrosterone pretreatment alters the ischemia/reperfusion-induced VEGF, IL-1, and IL-6 gene expression in acute renal failure. Kidney Blood Press. Res. 32, 175-184.
50. Vaudry, D., Falluel-Morel, A., Bourgault, S., Basille, M., Burel, D., Wurtz, O., Fournier, A., Chow, B. K., Hashimoto, H., Galas, L., Vaudry, H. (2009) Pituitary adenylate cyclase activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev. 61, 283-357.
51. Wei, Y., Mojsov, S. (1996) Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology. J. Neuroendocrinol. 8, 811-817.
52. Zhou, X., Rodriguez, W. I., Casillas, R. A., Ma, V., Tam, J., Hu, Z., Lelievre, V., Chao, A., Waschek, J. A. (1999) Axotomy-induced changes in pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP receptor gene expression in the adult rat facial motor nucleus. J. Neurosci. Res. 57, 953-961.